OSIC Announces Winners of Pulmonary Fibrosis Progression Challenge

OSIC Announces Winners of Pulmonary Fibrosis Progression Challenge

The Open Source Imaging Consortium (OSIC), a nonprofit collaborative group focused on combatting lung diseases, announced the winners of a competition that challenged scientists to design artificial intelligence (AI) programs that predict lung function decline in people with pulmonary fibrosis. Broadly, AI refers to computer systems that are able…

Focusing on What Is Still Possible This Holiday Season

This holiday season will be far different from previous ones. Because we are still in the midst of a global health crisis that won’t be resolved by Christmas, families must make difficult decisions about how to celebrate the holiday season this year. As a Canadian, I haven’t paid close attention…

Moving On: A Room-by-Room Remembrance Ritual

We moved out of our house today. Tomorrow, my husband, Jonny, our two pets, and I will board a plane for a new life in a new place. We are leaving Washington state behind for good. While I am sad to leave my friends, closing this chapter feels like a…

Treprostinil Earns FDA Orphan Drug Designation for Treating IPF

The U.S. Food and Drug Administration (FDA) has granted treprostinil orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug designation is given to therapies with the potential to substantially improve treatment for rare diseases (conditions affecting fewer than 200,000 people in the U.S.). The designation…